DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Abituzumab
Abituzumab
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0121788 A1
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Andrew Lai Thesis
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
The Two Tontti Tudiul Lui Hi Ha Unit
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Perspektive 2023
London - Westminster Research Ethics Committee
(INN) for Biological and Biotechnological Substances
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
14-350 Phrma Cancer2014 1001.Indd
(INN) for Biological and Biotechnological Substances
International Nonproprietary Names for Pharmaceutical Substances (INN)
Integrins As Therapeutic Targets: Successes and Cancers
Integrin-Mediated Tgfβ Activation Modulates the Tumour Microenvironment
Ongoing Clinical Trials and Treatment Options for Patients with Systemic SclerosisAssociated Interstitial Lung Disease
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Top View
Oncology Drugs in the Pipeline
Metastatic Dormant Cancer Cells So-Yeon Park1,2 and Jeong-Seok Nam1,2
Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
Supporting Information the Therapeutic Antibody Profiler (TAP): Five Computational De- Velopability Guidelines
Crenezumab - Drugbank
(19) United States Mar. 12, 2015
WO 2015/038818 A2 19 March 2015 (19.03.2015) P O P C T